ALLMedicine™ Gastrointestinal Stromal Tumors Center

Jun 24th, 2022 - Background: Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal soft tissue sarcoma, but remain a rare disease entity. Most GISTs are characterized by KIT or PDGFRA mutations, making them susceptible to tyrosine kinase inh...

Jun 23rd, 2022 - Since its approval in 2002, imatinib remains the standard first-line treatment for patients with advanced gastrointestinal stromal tumors (GISTs). Overall, all the drugs approved for patients who have developed secondary resistance to imatinib are...

Jun 21st, 2022 - This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult...

Jun 18th, 2022 - In the past few years, the sarcoma community has successfully completed several trials in patients with soft tissue sarcoma (STS) or gastrointestinal stromal tumor (GIST). The current review summarizes recently reported relevant trials or trial up...

Jun 15th, 2022 - Health-Related Quality of Life (HRQoL) is crucial for shared decision-making. The "Patient-Reported Outcome measures in Sarcoma" (PROSa) study evaluated HRQoL in general. We evaluated the transferability of PROSa data to clinical practice for the ...

Dec 26th, 2018 - Tyrosine kinase inhibitors (TKIs) have improved the overall survival of patients with gastrointestinal stromal tumors (GISTs), but their side effects can impact dose intensity and, consequently, the clinical benefit. To date, no guideline or conse...

Jul 30th, 2014 - The use of potential surrogate end points for overall survival, such as disease-free survival (DFS) or time-to-treatment failure (TTF) is increasingly common in randomized controlled trials (RCTs) in cancer. However, the definition of time-to-even...

Nov 20th, 2012 - Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2012| ,|therapeutic use,diagnosis,genetics,therapy,diagnosis,genetics,therapy,therapeutic use,therapeutic use,

May 9th, 2008 - Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.|2008|Casali PG,Jost L,Reichardt P,Schlemmer M,Blay JY,|diagnosis,epidemiology,pathology,therapy,

Jun 24th, 2022 - Background: Gastrointestinal stromal tumors (GISTs) are the most common gastrointestinal soft tissue sarcoma, but remain a rare disease entity. Most GISTs are characterized by KIT or PDGFRA mutations, making them susceptible to tyrosine kinase inh...

Jun 21st, 2022 - This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered orally (PO), in adult...

Jun 15th, 2022 - KIT is a receptor tyrosine kinase that binds to stem-cell factor (SCF), activating a series of downstream effector pathways. KIT is an established therapeutic target in cancer with activating mutations of KIT, such as gastrointestinal stromal tumo...

Jun 8th, 2022 - The purpose of this study is to collect and store normal and malignant tissue from patients with gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal mesothelioma, anal cancer ...

Jun 7th, 2022 - Assessing MRD (Minimal Residual Disease) and predicting the recurrence risk of tumor patients based on liquid biopsy ctDNA have been exploratory studies and applications in many cancer types, but for stromal-derived tumors such as gastrointestinal...

May 5th, 2022 - Although molecular biomarkers are becoming increasingly relevant in cancer care, community oncologists confront a plethora of challenges in translating research findings into practice. Structural changes in payment systems and decision-support too...

Jan 27th, 2022 - The multitargeted tyrosine kinase inhibitor ripretinib (Qinlock) showed comparable efficacy and less toxicity compared with sunitinib (Sutent), but failed to improve progression-free survival (PFS), a phase 3 trial of adults with advanced gastroin...

Dec 3rd, 2021 - Guidelines for the diagnosis, treatment, and follow-up of gastrointestinal stromal tumors (GISTs) were published in September 2021 by the European Society for Medical Oncology (ESMO), European Reference Network for Rare Adult Solid Cancers (EURACA...

Nov 10th, 2021 - The paradox of the PSA test. (MIT Press) Helping patients with cancer feel more like someone who matters and less like a number. (Time) Deciphera Pharmaceuticals announced that the switch-control tyrosine kinase inhibitor ripretinib (Qinlock) fail...

Oct 6th, 2021 - William D. Tap, MD Section Chief, Sarcoma Oncology Melanoma and Sarcoma Services Memorial Sloan-Kettering Cancer Center New York, NY The list of agents currently available to treat soft-tissue sarcoma is rather sh...